Biocept agrees $15 million common stock purchase agreement with Aspire

[News]

Biocept, Inc., a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection, monitoring and treatment of cancer, announces a $15 million common stock purchase agreement with Aspire Capital Fund, LLC, a Chicago-based institutional investor.

More... (http://www.news-medical.net/news/20151222/Biocept-agrees-2415-million-common-stock-purchase-agreement-with-Aspire.aspx)